Shares in Edwards Lifesciences Corp. rose after reporting first quarter results that beat analysts’ expectations.
“Building on a year in 2025 marked by solid financial performance and strategic progress, we delivered another strong quarter in Q1,” Edwards Chief Executive Bernard Zovighian said in a statement.
The Irvine-based medical device company posted revenue of $1.65 billion, surpassing the $1.6 billion expected by analysts. Earnings per share of 78 cents also topped analysts’ forecast of 73 cents.
Shares in Edwards rose 4.7% to $83.49 apiece in after-hours trading (NYSE: EW). They had ended regular trading at $79.92 and a $46 billion market cap.
The company said that due to stronger-than-expected first quarter results, it’s raising full-year sales growth guidance to 9% to 11%, up from 8% to 10%.
